GlassScriptPhysician profile
Kal Peterman
NPI 1093480246
$699.58
in general payments reported to CMS, 2019-2025
10 companies · $68.81 in 2025
The $68.81 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $42.49 · 2023: $533 · 2024: $54.85 · 2025: $68.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $168.80 | 2023 | Rybelsus, Ozempic |
| Mannkind Corporation | $139.69 | 2023-2025 | Afrezza |
| Lilly USA, LLC | $101.04 | 2023 | Taltz, Mounjaro, Trulicity |
| Tandem Diabetes Care, INC. | $82.80 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $57.38 | 2022-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $54.07 | 2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $35.65 | 2023 | Benlysta |
| Medtronic, INC. | $20.80 | 2023 | Inpen Smart Insulin Delivery System |
| Amgen INC. | $20.03 | 2023 | Repatha |
| Amryt Pharma Holdings LTD | $19.32 | 2023 | Mycapssa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kal Peterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.